Assessment of EPS and tardive dyskinesia in clinical trials

Herbert Y. Meltzer*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

36 Scopus citations


The incidence of acute extrapyramidal symptoms (EPS) - akathisia, dystonia, and parkinsonism - associated with traditional antipsychotics varies, but most researchers agree that neuroleptic-induced EPS occur in 50% to 75% of patients who take conventional antipsychotics. Atypical antipsychotics were developed to widen the therapeutic index and to reduce EPS. Although the mechanisms are unclear, the risk of EPS is less with the novel antipsychotics than with conventional drugs, and agents that produce low levels of acute EPS are likely to produce less tardive dyskinesia. Nevertheless, clinicians should exercise caution when comparing data from investigations of the novel antipsychotics and, until long-term data become available, should administer the new drags at doses below the EPS-producing level.

Original languageEnglish (US)
Pages (from-to)23-27
Number of pages5
JournalJournal of Clinical Psychiatry
Issue numberSUPPL. 12
StatePublished - Oct 5 1998

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Assessment of EPS and tardive dyskinesia in clinical trials'. Together they form a unique fingerprint.

Cite this